fda compounding peptides bpc-157 warning panel narrowly backs unapproved peptide drugs – NBC4 Washington New US FDA AdComm Members

The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks

BPC-157, a stable 15-amino acid pentadecapeptide derived from gastric protective factors, activates the FAK-paxillin and VEGFR2-Akt-eNOS signaling cascades that drive cellular migration, angiogenesis, and wound closure with exceptional stability under diverse physiological conditions

The two main methods for lowering serum Hcy levels are oral FA or 5-MTHF administration or intramuscular injections of FA

Identifying High-Risk Populations Some groups face a higher risk of B12 deficiency due to medication

This keeps injection volumes manageable and well within the range of a standard 1 mL insulin syringe